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Abstract
Background: Natural plants, including common vegetables and fruits, have been recognized as essential sources
for drug discovery and the development of new, safe, and economical medicaments. Stauntonia hexaphylla
(Lardizabalaceae) is widely distributed in Korea, Japan, and China, and is a popular herbal supplement in Korean
and Chinese folk medicine owing to its analgesic, sedative, and diuretic properties. However, the exact
pharmacological effects of S. hexaphylla extract, particularly its effect on osteoclastogenesis, are not known.
Methods: Osteoclast differentiation and function were identified with tartrate-resistant acid phosphatase (TRAP)
staining and bone resorption assay, and the underling mechanisms were determined by real-time RT-PCR and
western blot analysis.
Results: S. hexaphylla was found to inhibit early-stage receptor activator of nuclear factor-κB (NF-κB) ligand
(RANKL)-mediated osteoclast differentiation in bone marrow macrophages (BMMs) without cytotoxicity and
bone-resorbing activity in mature osteoclasts in a dose-dependent manner. This S. hexaphylla-mediated blockade of
osteoclastogenesis involved abrogation of the NF-κB, ERK, and c-Src-Btk-PLCγ2 calcium signal pathways. Interestingly, we
found that S. hexaphylla down-regulated RANKL-associated c-Fos protein induction by suppressing its translation.
Furthermore, ectopic overexpression of c-Fos and NFATc1 rescued the inhibition of osteoclast differentiation by S.
hexaphylla. Furthermore, S. hexaphylla inhibited the c-Fos- and NFATc1-regulated expression of genes required for
osteoclastogenesis, such as TRAP, OSCAR, β3-integrin, ATP6v0d2, and CtsK.
Conclusions: These findings suggest that S. hexaphylla might be useful for the development of new anti-osteoporosis
agents.
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Background
Osteoporosis, characterized by abnormally low bone
mineral density and micro-architectural degeneration
of bone tissue, is a progressive systemic skeletal disease
with various causes, including menopause; advanced
age; low calcium and vitamin D intake; and lack of
exercise due to long-term bed rest, especially in the eld-
erly population [1–3]. Current anti-osteoporosis drugs
such as estrogen, raloxifene, bisphosphonates, and cal-
citonin have been widely used, and their bone protect-
ive mechanisms are based on the inhibition osteoclastic
bone resorption. However, these drugs have numerous
side effects, causing many patients to discontinue their
use [4–7]. Hence, to prevent or reverse osteolytic bone
diseases, it is necessary to develop novel agents that
have fewer undesirable side effects.
Osteoclasts are specialized, multinucleated, and bone-
resorbing cells that form part of the mononuclear
phagocyte system [1]. They are formed by the fusion of
circulating mononuclear precursor cells of hematopoietic
origin. Osteoclast differentiation is critically regulated by
macrophage colony-stimulating factor (M-CSF) and re-
ceptor activator of nuclear factor-kappa B (NF-κB) ligand
(RANKL) [1, 8, 9]. M-CSF stimulates the expression of
RANK, the receptor for RANKL, and supports the sur-
vival and proliferation of osteoclast precursors [9].
RANKL stimulates differentiation of precursors into oste-
oclasts by inducing the expression of osteoclast-specific
genes, including tartrate-resistant acid phosphatase
(TRAP), osteoclast-associated receptor (OSCAR), and ca-
thepsin K (CtsK) [1, 8, 10]. The RANK/RANKL pathway
is considered to be an attractive therapeutic target for
bone destructive diseases. Although a more detailed
mechanism is still expected to be unveiled, the major sig-
naling events have been elucidated: RANK/RANKL bind-
ing activates downstream early signaling pathways,
including mitogen-activated protein kinase (MAPK) path-
ways and NF-κB, by recruitment of TNF-receptor associ-
ated factor 6 (TRAF6), which regulates transcription
factors involved in osteoclast differentiation [11, 12]. Sub-
sequently, RANKL induces the expression of c-Fos and
nuclear factor of activated T-cells, cytoplasmic 1
(NFATc1), key transcription factors for osteoclastogenesis
[13–15]. NFATc1 is a master regulator of terminal osteo-
clastogenesis, and autoamplification of NFATc1 depends
on activator protein (AP)-1 complex containing c-Fos and
NF-κB [15]. In addition, the RANKL/RANK signaling
pathway activates Ca2+ signaling through the activation of
phospholipase Cγ (PLCγ) [16, 17]. PLCγ regulates protein
kinase C (PKC) activation, intracellular Ca2+ levels, and
NFATc1 expression in hematopoietic systems [16, 18].
During osteoclastogenesis, increased Ca2+ levels induce
NFATc1 dephosphorylation and NFATc1 translocation
into the nucleus. Calcineurin inhibitors, such as FK506
and cyclosporine A, as well as the Ca2+ chelator
BAPTA-AM, potently suppress RANKL-induced oste-
oclastogenesis through inhibition of NFATc1 nuclear
translocation [19].
Recently, many plants and their extracts have been
recognized as useful sources for the prevention and
treatment of bone-related disorders. Stauntonia hexa-
phylla (Lardizabalaceae) is widely distributed in
thickets in lowlands and foothills in warmer regions of
Korea, Japan, and China. S. hexaphylla has been used
in Chinese folk medicine as analgesics, sedatives, and
diuretics [20]. As part of a search for bioactive com-
pounds, methanol extract from the aerial part of S.
hexaphylla was found to exhibit significant cytotoxic
activity and anti-cancer effects on HCT116 human
colon cancer cells [21]. However, the exactly pharma-
cological effect of S. hexaphylla remains unknown; in
particular, the effect of S. hexaphylla on osteoclast dif-
ferentiation and pathological bone destruction has not
yet been well defined. In this study, we have investi-
gated the effects of S. hexaphylla on osteoclast differ-




Methanol extract from the S. hexaphylla leaf was pur-
chased from the Korean Plant Extract Bank (Daejeon,
Korea). Recombinant soluble human M-CSF and RANKL
were obtained from PeproTech EC Ltd. (London, UK).
Monoclonal β-actin antibody was obtained from Sigma
(St. Louis, MO, USA). Anti-Akt, anti-phospho-Akt, anti-
p38, anti-phospho-p38, anti-JNK, anti-phospho-JNK, anti-
phospho-IκB, and anti-phospho-PLCγ2 were purchased
from Cell signaling Technology Inc. (Beverly, MA, USA).
Anti-c-Fos, anti-NFATc1, anti-IκB, and anti-PLCγ2 were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Fetal bovine serum (FBS), α-minimum essen-
tial medium (α-MEM), and penicillin/streptomycin were
purchased from Gibco BRL (Grand Island, NY, USA). All
other chemicals were of analytical grade or complied with
the standards required for cell culture experiments. Cyclo-
hexamide (CHX), MG132, and Ac-Leu-Leu-nle-h (ALLN)
were obtained from Calbiochem (San Diego, CA, USA).
Mice and in vitro osteoclastogenesis assay
BMMs isolation was performed in accordance with the
guidelines for animal experimentation of the Institu-
tional Animal Care and Use Committee of Wonkwang
University (WKU15-48, committee member: Sung Yeon
Kim, Jungkee Kwon, Hong Geun Oh, Hong-Seob So,
Okjin Kim, Chun-Soo Ko). Five-week-old male ICR
mice were purchased from Damul Science (Daejeon,
Korea). The mice were housed in cages in a controlled
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temperature (22–24 °C) and humidity (55–60 %) room
with a 12 h light/dark cycle. Bone marrow cells (BMCs)
were obtained from 5-week-old male ICR mice by
flushing the tibias and femurs with α-MEM supple-
mented with 10 % FBS, penicillin (100 U/mL), and
streptomycin (100 μg/mL). To obtained bone marrow
macrophages (BMMs) for osteoclast differentiation of
primary BMCs, the cells were cultured in α-MEM sup-
plemented with 10 % FBS and M-CSF (10 ng/mL) for
1 day on culture dishes. Non-adherent cells were trans-
ferred to 10 cm petri dishes and further cultured in the
presence of M-CSF (30 ng/mL) for 3 days. Adherent
cells were used as BMMs or as osteoclast precursors, after
the non-adherent cells were removed. To generate osteo-
clasts from the BMMs culture system, cells were cultured
with M-CSF (30 ng/mL) and RANKL (100 ng/mL) in the
presence or absence of S. hexaphylla on 48-well plates,
placed in an incubator set to 37 and 5 % CO2, and allowed
to incubate for 3 days. The cells were fixed in 3.7 % forma-
lin for 10 min, permeabilized with 0.1 % Triton X-100,
and then stained with TRAP solution. TRAP-positive mul-
tinucleated cells (MNCs) with more than three nuclei
were counted as osteoclasts.
PCR primers and quantitative real-time RT-PCR
Oligonucleotides used in this experiment were com-
mercially synthesized by Bioneer Co. (Daejeon, Korea).
Real-time RT-PCR analysis was performed using an
ExicyclerTM 96 Real-Time Quantitative Thermal Block
(Bioneer Co.). The real-time RT-PCR reactions were
conducted with initial denaturation for 10 min at 95 °C,
followed by 40 cycles of denaturation for 1 min at 95 °
C, annealing for 30 s at 60 °C, and extension for 1 min
at 72 °C. The expression of target molecules was ana-
lyzed using SYBR Green-based real-time RT-PCR, and
normalized to the expression of GAPDH. The primer
sets used in the quantitative real-time RT-PCR are
shown in Table 1.
Cytotoxicity assay
Cell proliferation was measured using the XTT assay kit
(Sigma). The BMMs (1 × 104/well) were seeded in 96-
well plates with various concentrations of S. hexaphylla
and cultured for 3 days in the presence of M-CSF
(30 ng/mL). For the last 4 h of culture, 50 μL of XTT
solution was added, and the plate was read at 450 nm
with an ELISA reader (Molecular Devices, CA, USA).
Western blot analysis
After the specified treatment, cells were washed twice
with cold-PBS and lysed with lysis buffer containing
50 mM Tris–HCl, 150 mM NaCl, 5 mM EDTA, 1 % Tri-
ton X-100, 1 mM sodium fluoride, 1 mM sodium vanad-
ate, 1 % deoxycholate, and protease inhibitors. The
protein concentration was determined using a Bio-Rad
DC protein assay kit (Bio-Rad Laboratories., Hercules,
CA, USA). The same amount of protein (15–30 μg) was
separated using 10 % SDS-polyacrylamide gel and trans-
ferred to a polyvinylidene difluoride (PVDF, Millipore,
Bedford, MA, USA) membrane for 90 min at 25 V on an
XCell II blot module (Invitrogen, Carlsbad, CA, USA).
The PVDF membranes were placed in 5 % nonfat milk
in tris-buffered saline with 0.1 % Tween 20 (TBST) for
1 h, washed, and incubated with the primary antibodies
for 2 h at room temperature. The membranes were
washed in TBST, and incubated for 1 h with various
HRP-conjugated donkey anti-rabbit, sheep anti-mouse
IgG secondary antibodies. The immunoreactive signals
were detected using the Western Chemiluminescent
HRP substrate kit (Millipore, Billerica, USA).
Bone resorption assay
Primary osteoblast cells (1 × 106 cells) and BMCs (1 × 107
cells) were cultured on collagen-gel-coated culture dishes
for 7 days in the presence of 10−8 M 1,25-dihydroxyvitamin
D3 (Sigma) and 10−6 M prostaglandin E2 (PGE2) (Sigma).
The co-cultured osteoclasts were detached by 0.1 % colla-
genase treatment at 37 °C for 10 min and then placed on
dentine slices or hydroxyapatite coated plates (Corning,
NY, USA) with or without S. hexaphylla. After 24 h, the
cells were removed, and the total resorption pits were ob-
served under a microscope and then quantified using
Image-Pro Plus version 4.0 (Media Cybernetics, Silver
Spring, MD, USA).
Retrovirus preparation and infection
Plat-E retroviral packaging cells were transfected by
pMX-IRES-EGFP, pMX-c-Fos-IRES-EGFP, and pMX-
CA-NFATc1-IRES-EGFP using X-tremeGENE 9 (Roche,
Nutley, NJ, USA) according to the manufacturer’s proto-
col. The culture supernatant of the retrovirus-producing
cells was collected for retroviral infection on BMMs that
were cultured with BMCs in M-CSF (30 ng/mL) for
Table 1 The oligonucleotides used as primers
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2 days. The BMMs were incubated with the retrovirus
soup produced by Plat-E cells together with polybrene
(10 μg/mL) and M-CSF (10 ng/mL) for 6 h. Infected
BMMs were further cultured in the presence of M-CSF
(30 ng/mL) and RANKL (100 ng/mL) with or without S.
hexaphylla for 3 days. Osteoclast formation was de-
tected by TRAP staining.
c-Fos stability
The BMMs were incubated with c-Fos retro-virus soup
produced by Plat-E cells together with polybrene
(10 μg/mL) and M-CSF (10 ng/mL) for 6 h. Infected
BMMs were pretreated with or without S. hexaphylla
in the presence of M-CSF for 24 h, and then stimulated
with RANKL. After 20 h, 2 μg/mL CHX, 5 μM MG132,
and 20 μM ALLN were added to the cultures for 4 h
before harvest.
Statistical analysis
Experiments were conducted at least three times, and
the data are expressed as the mean ± standard deviation
(SD). All statistical analyses were conducted using the
Statistical Package for the Social Sciences Software
(SPSS; Korean version 14.0). Most of the statistical dif-
ferences were analyzed using one-way ANOVA followed
by Tukey’s post hoc test. P-values of less than 0.05 were
considered statistically significant.
Results
S. hexaphylla suppresses RANKL-induced osteoclast differ-
entiation in BMMs and bone resorption by
co-cultured mature osteoclast
To identify the efficacy of S. hexaphylla on RANKL-
induced osteoclastogenesis, BMMs were cultured in the
presence of RANKL and M-CSF treated with or without
various concentrations of S. hexaphylla. However, RANKL
differentiated the BMMs of the control into TRAP-
positive MNCs, and S. hexaphylla dose-dependently de-
creased the formation of TRAP- positive MNCs (Fig. 1a
and b). Next, we evaluated the XTT assay to determine
whether the inhibitory effect of S. hexaphylla on osteoclas-
togenesis was due to reduced viability or proliferation of
the osteoclast precursor cells. S. hexaphylla had no cyto-
toxic effects, did not affect cell proliferation, and inhib-
ited osteoclast differentiation (Fig. 1c). To determine
the time course of the inhibitory effect of S. hexaphylla
on osteoclast differentiation, BMMs were cultured by
treatment with S. hexaphylla (50 μg/mL) at four differ-
ent time points with RANKL and M-CSF. The cells in-
cubated for 24 h in an S. hexaphylla-containing
medium, and were then transferred to an S. hexa-
phylla-free medium. As shown in Fig. 1d, the time
frames in which S. hexaphylla most effectively sup-
pressed osteoclast formation were days 0–1 and 1–2.
However, its inhibitory effect was slightly weaker on
days 2–3 and 3–4 (Fig. 1d and e). These finding suggest
that S. hexaphylla exerts an inhibitory effect on early
differentiation. We next examined whether S. hexa-
phylla can reduce the function of mature osteoclasts.
Mature osteoclasts were cultured on hydroxyapatite-
coated plates in the presence of S. hexaphylla. The
addition of S. hexaphylla clearly inhibited bone re-
sorption activity relative to the DMSO control (Fig. 1f
and g).
S. hexaphylla suppresses RANKL-induced ERK, NF-κB, and
Ca2+ signaling pathways
RANKL binding to RANK results in the recruitment of
multiple downstream signaling pathways such as Akt,
p38, JNK, ERK, and NF-κB. We examined the effect of
S. hexaphylla on RANKL-induced early signaling. As
shown in Fig. 2a, RANKL-induced phosphorylation of
p38, JNK, and Akt was not affected by S. hexaphylla
treatment, but S. hexaphylla inhibited the phosphorylation
of ERK and degradation of IκB. We next examined
whether S. hexaphylla alters the RANKL-PLCγ2-Ca2+-re-
lated signal pathway in which Ca2+ oscillation is followed
by promotion of NFATc1. S. hexaphylla completely
blocked RANKL-mediated c-Src, Btk, and PLCγ2 phos-
phorylation (Fig. 2a and b).
S. hexaphylla downregulates RANKL-induced expression
of NFATc1 and c-Fos stability
c-Fos and NFATc1 are key transcription factors in
RANKL-induced osteoclast differentiation, and they
regulate expression of the genes involved in osteoclast
differentiation and function such as TRAP, OSCAR,
and CtsK. Therefore, we investigated c-Fos and NFATc1
mRNA expression. As previously reported, c-Fos and
NFATc1 expression was upregulated in BMMs by
RANKL stimulation. S. hexaphylla decreased the
increased expression of the c-Fos protein by RANKL
without any marked changes in c-Fos mRNA expres-
sion (Fig. 3a and b). Next, we examined whether
S. hexaphylla promotes c-Fos protein degradation.
After 48 h post-transfection with c-Fos, the cells
treated with CHX, an inhibitor of protein synthesis,
decreased c-Fos protein expression compared to con-
trol (Fig. 3c); additional S. hexaphylla treatment accel-
erated this decrease in c-Fos protein levels; and the
effect of S. hexaphylla was reversed by co-treatment
with selective proteasome inhibitors, namely, MG132
or ALLN. These results suggest that proteasome-
mediated degradation is related to the S. hexaphylla-
induced reduction in c-Fos protein (Fig. 3c). Next, we
examined whether forced expression of c-Fos and
NFATc1 was sufficient to reverse the inhibitory effect
of S. hexaphylla on osteoclast differentiation. The
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ectopic expression of c-Fos and NFATc1 fully reversed
the inhibitory effect of S. hexaphylla on RANKL-
induced osteoclast differentiation (Fig. 3d-f ). These
results indicate that the effect of S. hexaphylla may in-
volve the inhibition of c-Fos and NFATc1 during
RANKL-mediated osteoclastogenesis.
Fig. 1 S. hexaphylla suppresses RANKL-induced osteoclast differentiation in BMMs and bone resorption by co-cultured mature osteoclasts. a BMMs
were cultured with M-CSF (30 ng/mL) and RANKL (100 ng/mL) for 3 days in the presence or absence of S. hexaphylla. b After culturing, cells were
fixed with 3.7 % formalin in PBS, permeabilized with 0.1 % Triton X-100 in PBS, and stained with TRAP staining solution; TRAP-positive MNCs were
then counted. c BMMs were cultured for 3 days with the indicated doses of S. hexaphylla in the presence of M-CSF (30 ng/mL). Cell viability was
analyzed using an XTT assay. d BMMs were cultured as in (a), except that the cells were treated with S. hexaphylla on the indicated days. e After
culturing, cells were fixed, and the number of TRAP-positive MNCs was counted. f pOBs and BMCs were co-cultured on a collagen-matrix-coated
plate for 6 days, and the flourishing osteoclasts were harvested. Mature osteoclasts were seeded on hydroxyapatite-coated plates with or without
S. hexaphylla for 24 h. Attached cells on the plates were removed and photographed under a light microscope. Pit areas were quantified using
Image J (g), and bone resorption numbers were counted using a light microscope. ***P < 0.001; versus vehicle (DMSO)
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S. hexaphylla inhibits RANKL-induced mRNA expression of
OSCAR, TRAP, ATP6v0d2, β3-integrin, and CtsK
NFATc1 regulates the expression of OSCAR, TRAP,
ATP6vod2, β3-integrin, and CtsK during RANKL-
induced osteoclastogenesis. We determined whether S.
hexaphylla regulates the expression of OSCAR, TRAP,
ATP6vod2, β3-integrin, and CtsK. S. hexaphylla down-
regulated the expression of OSCAR and TRAP, which
are genes related to osteoclast formation. S. hexaphylla
also decreased the expression of ATP6vod2 and β3-integ-
rin, which affect cell-to-cell migration or fusion. The ex-
pression of CtsK and its associated bone-resorbing
activity was inhibited by S. hexaphylla (Fig. 4), suggest-
ing that the inhibitory effect of S. hexaphylla on
RANKL-mediated NFATc1 expression is followed by the
down-regulation of osteoclastogenic marker genes.
Discussion
There is a growing interest in the efficacy of natural plant
products for the prevention and treatment of bone-related
disorders such as osteoporosis and rheumatoid arthritis.
In this study, we have shown that S. hexaphylla effectively
inhibits RANKL-induced osteoclast differentiation at the
early stages without any cytotoxicity or bone-resorbing ac-
tivity by mature osteoclasts (Fig. 1).
RANK/RANKL interaction forms a fundamental
cytokine system that is capable of influencing all as-
pects of osteoclast differentiation, function, and (indir-
ectly) the complete bone regulatory system [10, 12].
The connection between RANK and RANKL induces
recruitment and activation of TRAF6, which leads to
multiple downstream cascades. The signals are com-
posed of six known signal pathways: ERK, p38, JNK,
NF-κB, Src, and Akt. We found that by suppressing
RANKL-mediated ERK and NF-κB signaling, S. hexa-
phylla inhibited osteoclast differentiation (Fig. 2a). In
previous studies, compared to WT mice, ERK1 defi-
ciency reduced the number of osteoclast progenitors
and the formation of TRAP-positive cells on the tra-
becular surface [22]. In addition, NF-κB is an import-
ant signal mediator of inflammatory and immune
reactions, and is a major transcription factor for
RANKL-activated osteoclastogenesis [23]. IκB is bound
to NF-κB, which prevents it from translocating to the
nucleus, and phosphorylation by IKK separates the two
proteins. Subsequent ubiquitination and proteasomal
degradation of IκB allows NF-κB to translocate into the
nucleus and stimulate the transcription of the target
gene [24]. NF-κB p50/p52 double knockout mice exhibit
osteoclastogenesis defects and severe osteopetrosis [25, 26].
S. hexaphylla also induces osteoclastogenesis through the
c-Src-Btk-PLCγ2 signaling pathway (Fig. 2b). c-Src de-
ficiency produces an osteopetrotic skeletal phenotype
and affects the bone-resorbing activity of mature oste-
oclasts [27, 28]. PLCγ activates Ca2+ signaling and
NFATc1 in immune cells. PLCγ2 deficiency in mouse
cells lowers the expression of NFATc1 RANKL-
stimulation relative to wild mice [29].
Fig. 2 S. hexaphylla suppresses RANKL-induced ERK, NF-κB, and Ca2+ signaling pathways. BMMs were starved with serum-free α-MEM media for
3 h. BMMs were pretreated with S. hexaphylla for 1 h and then stimulated with RANKL for the indicated times. BMMs were pretreated with or
without S. hexaphylla for 1 h and then stimulated with RANKL (100 ng/mL) for the indicated time. The cell lysates were analyzed by western
blotting with antibodies. β-actin was used as the internal control
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Under normal conditions, the RANKL-RANK axis
appears to be essential for osteoclastogenesis, and
costimulatory immunoreceptors lead to robust in-
duction of c-Fos and NFATc1, which are the necessary
and sufficient transcription factors for osteoclast
differentiation. The crucial role of c-Fos in osteoclasto-
genesis was demonstrated by in vivo experiments using
genetically modified mice. c-Fos-deficient mice exhibit a
severe osteoporotic phenotype due to the failure of osteo-
clast differentiation [30]. NFATc1-deficient embryonic stem
Fig. 3 S. hexaphylla downregulates RANKL-induced expression of NFATc1 and c-Fos stability. BMMs were pretreated with S. hexaphylla for 1 h and
then stimulated with RANKL (100 ng/mL) for the indicated times. Total RNA or protein of c-Fos and NFATc1 were obtained at the indicated time
points, respectively. a mRNA expression of c-Fos and NFATc1 was analyzed by real-time RT-PCR. b Western blot analysis was performed with the
indicated antibodies. β-actin was used as an internal control. c BMMs were infected with pMX-c-Fos-IRES-EGFP (c-Fos). Infected BMMs were
pretreated with or without S. hexaphylla in the presence of M-CSF (30 ng/mL) for 24 h and then stimulated with RANKL (100 ng/mL). After 20 h,
2 μg/mL CHX, 5 μM MG132, and 20 μM ALLN were added to the cultures for 4 h before harvest. Western blot analysis was then performed on
the cells. d BMMs were infected with pMX-IRES-EGFP (control vector), pMX-c-Fos-IRES-EGFP (c-Fos), or (e) pMX-CA-NFATc1-IRES-EGFP (CA-NFATc1).
After infection, the cells were cultured in the presence of M-CSF and RANKL with or without S. hexaphylla. f TRAP-positive MNCs were counted.
***P < 0.001; versus vehicle (DMSO). ns: not significant; ***P < 0.001; *P < 0.05 versus vehicle (DMSO)
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cells are unable to differentiate into osteoclasts in response
to RANKL, and the forced expression of NFATc1 leads to
the formation of osteoclasts from BMMs in the absence of
RANKL [15]. In our study, S. hexaphylla suppressed
RANKL-induced NFATc1 mRNA and protein expression.
By contrast, c-Fos protein, but not mRNA, expression was
diminished (Fig. 3a and b). This suggests that S. hexa-
phylla-mediated inhibition of NFATc1 expression is not in-
volved in c-Fos transcriptional activity, and instead results
from the inhibition of c-Fos translational activity. Moreover,
the protein stability assay showed that the reduction in c-
Fos protein contributed to the suppression of c-Fos transla-
tion via proteasome-dependent degradation (Fig. 3c). Fur-
thermore, the forced expression of c-Fos or CA-NFATc1
rescued the S. hexaphylla-induced inhibition of osteo-
clast differentiation, which suggests that down-
regulation of c-Fos is responsible for the inhibitory ef-
fects of S. hexaphylla (Fig. 3d-f ).
NFATc1 has a crucial role in the regulation of osteo-
clastogenic marker genes during RANKL-mediated osteo-
clast differentiation, and it gradually induces the
expression of osteoclast-specific genes, including OSCAR,
TRAP, ATP6v0d2, β3-integrin, and CtsK [1, 8, 9]. The
present data suggest that S. hexaphylla suppressed the in-
duction of OSCAR, TRAP, ATP6v0d2, β3-integrin, and
CtsK (Fig. 4). Several proteolytic enzymes, including
OSCAR, TRAP, ATP6v0d2, and CtsK, have been shown to
play important roles in degrading the organic bone matrix,
and of these proteolytic enzymes have the highest levels in
osteoclasts. Matrix-degrading enzymes are also known
to be collagen-degrading enzymes, and can directly
degrade collagen in hard tissues that have been demi-
neralized. In addition, ανβ3-integrin is known to play a
role in the regulation of cell migration and the main-
tenance of the sealing zone required for effective
osteoclastic bone resorption. This indicates that S. hex-
aphylla extract inhibited bone resorption by disrupting
the induction of cytoskeletal organization, leading to
the formation of a ruffled border and the adhesion of
osteoclasts to the bone matrix.
Conclusions
In conclusion, this is the first study to report that S. hex-
aphylla efficiently suppresses RANKL-induced osteoclast
differentiation and bone-resorbing activity in vitro. S.
hexaphylla inhibits osteoclastogenesis via proteasome-
mediated degradation of c-Fos protein and suppression
of NFATc1 induction. These results suggest that S. hexa-
phylla has potential as a natural herbal therapy for
diseases associated with bone loss.
Fig. 4 S. hexaphylla inhibits RANKL-induced mRNA expression of OSCAR, TRAP, ATP6v0d2, β3-integrin, and CtsK. BMMs were pretreated with
S. hexaphylla for 1 h and then stimulated with RANKL (100 ng/mL) for the indicated times. Total RNA was obtained at the indicated time points,
respectively. The mRNA expression of OSCAR, TRAP, ATP6v0d2, β3-integrin, and CtsK was analyzed by real-time RT-PCR. ns: not significant; ***P <
0.001; **P < 0.01; *P < 0.05 versus vehicle (DMSO). ***P < 0.001; **P < 0.01; *P < 0.05 versus vehicle (DMSO)
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